Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma.
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Bortezomib
/ administration & dosage
Depsipeptides
/ administration & dosage
Dexamethasone
/ administration & dosage
Disease-Free Survival
Female
Humans
Lenalidomide
/ administration & dosage
Male
Middle Aged
Multiple Myeloma
/ drug therapy
Peptides, Cyclic
Survival Rate
Thalidomide
/ administration & dosage
Dexamethasone
Multiple myeloma
Plitidepsin
Refractory
Relapsed
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
09
01
2019
accepted:
12
06
2019
pubmed:
27
6
2019
medline:
28
8
2019
entrez:
27
6
2019
Statut:
ppublish
Résumé
The randomized phase III ADMYRE trial evaluated plitidepsin plus dexamethasone (DXM) versus DXM alone in patients with relapsed/refractory multiple myeloma after at least three but not more than six prior regimens, including at least bortezomib and lenalidomide or thalidomide. Patients were randomly assigned (2:1) to receive plitidepsin 5 mg/m
Identifiants
pubmed: 31240472
doi: 10.1007/s00277-019-03739-2
pii: 10.1007/s00277-019-03739-2
pmc: PMC6700046
doi:
Substances chimiques
Depsipeptides
0
Peptides, Cyclic
0
Thalidomide
4Z8R6ORS6L
Bortezomib
69G8BD63PP
Dexamethasone
7S5I7G3JQL
Lenalidomide
F0P408N6V4
plitidepsin
Y76ID234HW
Types de publication
Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
2139-2150Références
J Biol Chem. 2002 May 24;277(21):18545-51
pubmed: 11893745
J Biol Chem. 2003 Jan 3;278(1):241-50
pubmed: 12414812
Oncogene. 2004 Jun 10;23(27):4673-80
pubmed: 15122339
N Engl J Med. 2005 Jun 16;352(24):2487-98
pubmed: 15958804
J Cell Biochem. 2007 Feb 1;100(2):267-78
pubmed: 16888816
Leukemia. 2008 Feb;22(2):231-9
pubmed: 17972944
N Engl J Med. 2007 Nov 22;357(21):2123-32
pubmed: 18032762
Cancer Res. 2008 Jul 1;68(13):5216-25
pubmed: 18593922
PLoS One. 2010 May 21;5(5):e10755
pubmed: 20505761
Clin Cancer Res. 2010 Jun 15;16(12):3260-9
pubmed: 20530693
Blood. 2011 May 5;117(18):4691-5
pubmed: 21292775
Leukemia. 2012 Jan;26(1):149-57
pubmed: 21799510
Blood. 2012 Oct 4;120(14):2817-25
pubmed: 22833546
Blood. 2013 Oct 3;122(14):2331-7
pubmed: 23950178
Ann Oncol. 2013 Oct;24 Suppl 6:vi133-7
pubmed: 23956208
Lancet Oncol. 2013 Oct;14(11):1055-1066
pubmed: 24007748
Med Decis Making. 2014 Apr;34(3):387-402
pubmed: 24449433
Biochem Biophys Res Commun. 2014 Jul 18;450(1):1-6
pubmed: 24853801
Br J Haematol. 2015 Mar;168(6):820-3
pubmed: 25403264
Blood. 2016 Feb 11;127(6):713-21
pubmed: 26631116
Lancet. 2016 Apr 9;387(10027):1551-1560
pubmed: 26778538
Sci Rep. 2016 Oct 07;6:35100
pubmed: 27713531
Future Oncol. 2019 Jan;15(2):109-120
pubmed: 30111169
Br J Cancer. 1998 Sep;78(6):739-44
pubmed: 9743292